| First Author | Ali K | Year | 2014 |
| Journal | Nature | Volume | 510 |
| Issue | 7505 | Pages | 407-411 |
| PubMed ID | 24919154 | Mgi Jnum | J:213482 |
| Mgi Id | MGI:5585189 | Doi | 10.1038/nature13444 |
| Citation | Ali K, et al. (2014) Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510(7505):407-11 |
| abstractText | Inhibitors against the p110delta isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some human leukaemias. As p110delta is primarily expressed in leukocytes, drugs against p110delta have not been considered for the treatment of solid tumours. Here we report that p110delta inactivation in mice protects against a broad range of cancers, including non-haematological solid tumours. We demonstrate that p110delta inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression. Thus, p110delta inhibitors can break tumour-induced immune tolerance and should be considered for wider use in oncology. |
